NCT03861091View on ClinicalTrials.gov

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 12, 2019

Primary Completion Date

March 2, 2022

Study Completion Date

March 2, 2022

Conditions
Lung Neoplasm
Interventions
DRUG

risedronate

Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT

DRUG

Matching placebo

Dose not applicable, given once 7-21 days prior to initiation of SBRT

Trial Locations (2)

27157

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

27262

High Point Regional Medical Center, High Point

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03861091 - Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT | Biotech Hunter | Biotech Hunter